Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A.
Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, has raised $55 million in Series B financing, funds it will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up.
Finnish pharmaceutical firm Orion Oyj has signed a loan agreement of €100m with the European Investment Bank in Espoo.
BridgeBio Pharma, a clinical-stage biopharmaceutical firm focused on the development of medicines for genetic diseases, has secured $299.2m funds to advanced its existing drug research and development programs.
British drugmaker GlaxoSmithKline (GSK) has completed the acquisition of the US-based oncology-focused biopharmaceutical firm Tesaro for $5.1bn (£4bn).
Kyn Therapeutics, a US-based clinical-stage biotech company, has entered into a global collaboration with biopharma major Celgene to develop immuno-oncology therapies.
Juvenescence, a biopharmaceutical company focused on modifying ageing and age-related disease, has closed the first tranche of its Series B financing, in the amount of $46m.
Biomunex Pharmaceuticals has signed a licensing agreement with Sanofi for the development of bi-specific and multi-specific antibody therapeutics.
Bioharmony Therapeutics, a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, has entered into a collaborative research and licensing agreement with Boehringer Ingelheim to develop bacteriophage lysins for the treatment of multidrug resistant (MDR) Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections.
Ascletis Pharma (Ascletis, 1672.HK) and Suzhou Alphamab jointly announce that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for anti-PD-L1 KN035 to treat hepatitis B and other viral diseases in Greater China (Ascletis code: ASC22).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.